A Republican bill with 1 Democratic cosponsor · See all 4 cosponsors
Last activity — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
In committee
Introduced and handed to a committee in the chamber it started in.
The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.
Its path through Congress
- Introduced
- In Committee
What this bill would do
The Small Biotech Innovation Act aims to amend the Social Security Act to create an exception within the Medicare drug price negotiation program. This exception applies to research and development-intensive small biotech manufacturers starting in 2029. It exempts qualifying single source drugs from being considered negotiation-eligible drugs. To qualify, manufacturers must meet specific revenue investment thresholds in research and development and meet certain size and ownership requirements. The bill also outlines the application process and dispute resolution procedures for these manufacturers.
Yes· 3 of 4
- Scored +6
Does this make it easier to run a small business?
The bill provides significant relief for small biotech manufacturers by exempting them from Medicare price negotiations.
- Scored +5
Would business owners be better off under this?
The bill specifically benefits small biotech business owners through the negotiation exception.
- Scored +3
Does this put more money into scientific research?
The bill incentivizes higher R&D investment percentages for qualifying manufacturers.
The opposite· 3 of 7
- Scored -4
Does this lower the price of prescription medicines?
By exempting certain drugs from negotiation, the bill may result in higher drug costs for Medicare beneficiaries compared to the standard program.
- Scored -3
Would people over 65 be better off under this?
Seniors on Medicare may face higher costs for drugs that are no longer subject to price negotiation.
- Scored -3
Would retired people be better off under this?
Retirees relying on Medicare may face higher out-of-pocket costs for certain drugs.
Who it would affect, and how
Potential Positive Impacts for People
- Exception from drug price negotiations: Research and development-intensive small biotech manufacturers would have their qualifying single source drugs exempt from the Medicare drug price negotiation program starting in s price applicability year 2029 (Section 2, subparagraph (D)(i)).
Potential Negative Impacts for People
- Loss of exception upon acquisition: If a manufacturer is acquired after 2029 by a company that does not meet the definition of a research and development-intensive small biotech manufacturer, the drug will no longer be considered a qualifying single source drug under the exception (Section 2, subparagraph (D)(iii)).
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Demographic And Interest Groups
- Would business owners be better off under this? — The bill specifically benefits small biotech business owners through the negotiation exception. Would retired people be better off under this? — Retirees relying on Medicare may face higher out-of-pocket costs for certain drugs. Would people over 65 be better off under this? — Seniors on Medicare may face higher costs for drugs that are no longer subject to price negotiation. Would households on low incomes be better off under this? — Lower-income households may be more negatively impacted by higher prescription drug costs. Would people with disabilities be better off under this? — The exception could potentially increase the cost of necessary medications for people with disabilities. Would veterans be better off under this, taking everything together? — Veterans may face higher costs for drugs through the healthcare system due to the loss of negotiation exceptions.
- Economy And Finance
- Does this make it easier to run a small business? — The bill provides significant relief for small biotech manufacturers by exempting them from Medicare price negotiations. Does this reduce what the federal government spends? — The exemption from drug price negotiations may reduce the government's ability to lower Medicare spending on certain drugs.
- Education And Technology
- Does this put more money into scientific research? — The bill incentivizes higher R&D investment percentages for qualifying manufacturers.
- Healthcare
- Does this put more money into medical research? — The exception incentivizes biotech companies to reinvest higher percentages of revenue into research and development. Does this lower the price of prescription medicines? — By exempting certain drugs from negotiation, the bill may result in higher drug costs for Medicare beneficiaries compared to the standard program.
- 7/21/2026
- 1 Cosponsor added.
- 4/14/2026
- 1 Cosponsor added.
- 12/19/2025
- 1 Cosponsor added.
- 6/4/2025
- Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 1 Cosponsor added.
- Introduced in House
One bill Congress.gov lists as related to this one — companions in the other chamber, earlier versions, and bills this one absorbed or was folded into.
David KustoffRepublican · Tennessee
Nathaniel MoranRepublican · Texas
Lateefah SimonDemocrat · California
Claudia TenneyRepublican · New York